Evidence map›Paper›PMID 29391880›Full record

ArticleOncology letters2018

Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance.

Chenglong Wang, Qian Ye, Yijia Cao, Juan Tan, Fei Wang, Jin Jiang, Youde Cao

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. The C/C Genotype of rs1231760 inDiagnostics (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chenglong WangDepartment of Pathology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, P.R. China.
Qian YeDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Yijia CaoDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Juan TanDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Fei WangDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Jin JiangDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Youde CaoDepartment of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Chongqing Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes in the expression of regulator of G protein signaling 2 (RGS2) are involved in the genesis and development of a number of malignancies. However, the association between changes in the expression of RGS2 and breast invasive carcinoma of no special type (BIC-NST) remains unknown. The present study found that, in comparison to normal breast tissue, BIC-NST exhibited low expression of RGS2 mRNA and protein, as detected using data mining and immunohistochemical analysis. The low expression of RGS2 was associated with the positive status of hormone receptor expression in BIC-NST. Kaplan-Meier analysis revealed that patients with low RGS2 expression had a significantly poorer overall survival rate. Furthermore, multivariate Cox regression analysis demonstrated that the RGS2 low expression was an independent high-risk factor. Gene set enrichment analysis using data from The Cancer Genome Atlas supported these results. In summary, the results of the current study indicate that RGS2 acts as a suppressor gene in the progression of BIC-NST. To the best of our knowledge, the present study is the first concerning the association between RGS2 and hormone receptors in BIC-NST, as well as that between RGS2 expression and the prognosis of patients with BIC-NST. However, the effect of RGS2 in breast cancer requires further investigation.

Indexed as

breast invasive carcinoma of no special typedata miningimmunohistochemistryprognosisregulator of G protein signaling 2

Identifiers

PMID29391880
PMCPMC5769397
OpenAlexW2767009123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.